查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1813825

美国荷尔蒙疗法（零售）市场规模、份额和趋势分析报告：按产品、适应症、给药途径、分销管道和细分市场预测，2025-2033 年

U.S. Hormone Therapy (Retail Side) Market Size, Share & Trends Analysis Report By Product (Sex Hormones, Thyroid Hormones), By Indication, By Route of Administration (Oral, Parenteral), By Distribution Channel, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

市场规模与趋势：

预计 2024 年美国荷尔蒙疗法（零售）市场规模为 116.3 亿美元，到 2033 年将达到 192.2 亿美元，2025 年至 2033 年的复合年增长率为 5.83%。

这种增长是由人口老化和荷尔蒙失调盛行率上升所推动的，同时口服药丸、经皮吸收贴片、皮下丸剂和注射剂等给药技术的进步也提高了疗效、便利性和依从性。

此外，药局还提供便利的配药和咨询服务，Ro、Noom 和 Midi Health 等平台则将远端医疗、线上处方和荷尔蒙送货上门服务捆绑在一起，其中一些还结合了 GLP-1减重疗法，以推动销售。

目录

第一章调查方法与范围

第二章执行摘要

第三章市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场趋势与展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 法律规范
  • 商业环境分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
  • 线上线下通路定价分析
  • 消费者对荷尔蒙疗法的认知趋势
  • 直接面向消费者 (DTC)经营模式的影响

第四章 产品业务分析

  • 美国荷尔蒙疗法（零售）市场：产品差异分析
  • 美国荷尔蒙疗法（零售）市场：产品细分仪表板
  • 2024 年和 2033 年产品趋势和市占率分析
  • 按产品
  • 性荷尔蒙
    • 性荷尔蒙市场，2021-2033
    • 雌激素替代疗法（ERT）
    • 睾酮替代疗法（TRT）
    • 黄体素治疗
    • 合併荷尔蒙疗法
  • 甲状腺激素
  • 生长激素
  • 肾上腺激素
  • 其他荷尔蒙

第五章 指示业务分析

  • 美国荷尔蒙疗法（零售）市场：适应症变化分析
  • 美国荷尔蒙疗法（零售）市场：适应症细分仪表板
  • 2024 年和 2033 年适应症趋势和市场份额分析
  • 按指示
  • 管理更年期和男性更年期
  • 甲状腺机能低下症
  • 性腺功能低下
  • 生长激素缺乏症
  • 性别肯定疗法
  • 不孕不育治疗
  • 化妆品应用
  • 其他适应症

第六章 管理路线业务分析

  • 美国荷尔蒙疗法（零售）市场：给药途径变化分析
  • 美国荷尔蒙疗法（零售端）市场：给药途径细分仪表板
  • 2024 年和 2033 年给药途径趋势和市占率分析
  • 依给药途径
  • 口服
  • 肠外
  • 经皮
  • 其他给药途径

第七章通路业务分析

  • 美国荷尔蒙疗法（零售）市场：分销通路波动分析
  • 美国荷尔蒙疗法（零售）市场：分销通路细分仪表板
  • 2024年及2033年通路趋势与市占率分析
  • 按分销管道
  • 线下药局
    • 大型连锁店
    • 独立药房
  • 网路药局/远端医疗
    • 纯网路药局
    • 独立药房
  • 远端医疗和基于订阅的DTC品牌

第八章 竞争态势

  • 公司分类（线下药局）
  • 公司分类（网路药局）
  • 公司分类（荷尔蒙诊所）
  • 参与企业概况
    • Offline Pharmacies
    • Online Pharmacies
    • Specialized Hormone Clinics
  • 企业市场分析
  • 战略地图
    • 区域扩张
    • 併购
    • 其他的
  • 公司简介/上市公司
  • Offline Pharmacies
    • CVS Health
    • Walgreens Boots Alliance, Inc.
    • Walmart Pharmacy
    • Rite Aid Corp
    • The Kroger Co.
    • Albertsons
    • Publix
    • Costco Wholesale Corporation
    • Meijer, Inc.
  • Online Pharmacies
    • Hims &Hers Health, Inc
    • CVS Health
    • Ro (Roman Health Ventures Inc.)
    • Lemonaid Health, Inc.
    • Mark Cuban Cost Plus Drug Company, PBC
    • Amazon.com, Inc.
    • Blink Health Administration LLC, Inc.
    • GoodRx, Inc
    • Honeybee Health Inc.
    • TruePill
    • NURX Inc.
    • AgelessRx
  • Specialized Hormone Clinics
    • Hims &Hers Health, Inc
    • BodyLogicMD
    • Defy Medical
    • Renew Vitality
    • Victory Men's Health
    • Hone Health
    • Joi & Blokes
    • Ways2Well
    • Honeybee Health Inc.
    • 4Ever Young Anti-aging Solutions
    • T CLINICS USA
Product Code: GVR-4-68040-700-4

Market Size & Trends:

The U.S. hormone therapy (retail side) market size was estimated at USD 11.63 billion in 2024 and is projected to reach USD 19.22 billion by 2033, growing at a CAGR of 5.83% from 2025 to 2033. This growth is driven by an increasing aging population and rising hormonal disorder prevalence. In addition, advances in delivery technologies, including oral pills, transdermal patches, subcutaneous pellets, and injectables, have enhanced efficacy, convenience, and adherence.

Moreover, the pharmacies now offer convenient dispensing and counseling, and platforms such as Ro, Noom, and Midi Health bundle telemedicine, online prescribing, and at-home delivery of hormones, with some combining GLP-1 weight-loss treatments, driving sales upward.

U.S. Hormone Therapy (Retail Side) Market Report Segmentation

This report forecasts revenue growth at a country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. hormone therapy (retail side) market report based on product, indication, route of administration, and distribution channel:

  • Product Outlook (Revenue, USD Billion, 2021 - 2033)
  • Sex Hormones
    • Estrogen Replacement Therapy (ERT)
    • Testosterone Replacement Therapy (TRT)
    • Progesterone Therapy
    • Combined Hormone Therapy
  • Thyroid Hormones
  • Growth Hormones
  • Adrenal Hormones
  • Other Hormones
  • Indication Outlook (Revenue, USD Billion, 2021 - 2033)
  • Menopause & Andropause Management
  • Hypothyroidism
  • Hypogonadism
  • Growth Hormone Deficiency
  • Gender Affirming Therapy
  • Fertility Treatment
  • Cosmetic Applications
  • Other Indications
  • Route of Administration Outlook (Revenue, USD Billion, 2021 - 2033)
  • Oral
  • Parenteral
  • Transdermal
  • Other Route of Administration
  • Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
  • Offline Retail Pharmacies
    • Large chains
    • Independent pharmacies
  • Online Pharmacies / Telehealth
    • Pure-play online pharmacies
    • Telehealth & subscription-based DTC brands
  • Others (Specialized Hormone Clinics)

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Definitions
  • 1.2. Estimates and Forecast Timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
    • 1.4.5. Details of Primary Research
    • 1.4.6. Research Assumption
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Data Visualization
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. Objectives
    • 1.8.1. Objective - 1
    • 1.8.2. Objective - 2
    • 1.8.3. Objective - 3
  • 1.9. List of Secondary Sources
  • 1.10. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. U.S. Hormone Therapy (Retail Side) Market
    • 2.1.1. Market Snapshot
    • 2.1.2. Segment Snapshot
      • 2.1.2.1. Product & indication segment outlook
      • 2.1.2.2. Route of administration & distribution channel segment outlook
    • 2.1.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
    • 3.3.2. Market Restraint Analysis
  • 3.4. Regulatory Framework
  • 3.5. Business Environment Analysis Tools
    • 3.5.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.5.1.1. Supplier power
      • 3.5.1.2. Buyer power
      • 3.5.1.3. Substitution threat
      • 3.5.1.4. Threat of new entrants
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL Analysis
  • 3.6. Pricing Analysis in Online vs. Offline Channels
  • 3.7. Consumer Awareness Trends for Hormone Therapy
  • 3.8. Direct-to-Consumer (DTC) Business Models Impact

Chapter 4. Product Business Analysis

  • 4.1. U.S. Hormone Therapy (Retail Side) Market: Product Movement Analysis
  • 4.2. U.S. Hormone Therapy (Retail Side) Market: Product Segment Dashboard
  • 4.3. Product Movement & Market Share Analysis, 2024 & 2033
  • 4.4. U.S. Hormone Therapy (Retail Side) Market Estimates & Forecast, by Product
  • 4.5. Sex Hormones
    • 4.5.1. Sex Hormones Market, 2021 - 2033 (USD Million)
    • 4.5.2. Estrogen Replacement Therapy (ERT)
      • 4.5.2.1. Estrogen Replacement Therapy (ERT) market, 2021 - 2033 (USD Million)
    • 4.5.3. Testosterone Replacement Therapy (TRT)
      • 4.5.3.1. Testosterone Replacement Therapy (TRT) market, 2021 - 2033 (USD Million)
    • 4.5.4. Progesterone Therapy
      • 4.5.4.1. Progesterone therapy market, 2021 - 2033 (USD Million)
    • 4.5.5. Combined Hormone Therapy
      • 4.5.5.1. Combined hormone therapy market, 2021 - 2033 (USD Million)
  • 4.6. Thyroid Hormones
    • 4.6.1. Thyroid Hormones Market, 2021 - 2033 (USD Million)
  • 4.7. Growth Hormones
    • 4.7.1. Growth Hormones Market, 2021 - 2033 (USD Million)
  • 4.8. Adrenal Hormones
    • 4.8.1. Adrenal Hormones Market, 2021 - 2033 (USD Million)
  • 4.9. Other Hormones
    • 4.9.1. Other Hormones Market, 2021 - 2033 (USD Million)

Chapter 5. Indication Business Analysis

  • 5.1. U.S. Hormone Therapy (Retail Side) Market: Indication Movement Analysis
  • 5.2. U.S. Hormone Therapy (Retail Side) Market: Indication Segment Dashboard
  • 5.3. Indication Movement & Market Share Analysis, 2024 & 2033
  • 5.4. U.S. Hormone Therapy (Retail Side) Market Estimates & Forecast, by Indication
  • 5.5. Menopause & Andropause Management
    • 5.5.1. Menopause & Andropause Management Market, 2021 - 2033 (USD Million)
  • 5.6. Hypothyroidism
    • 5.6.1. Hypothyroidism Market, 2021 - 2033 (USD Million)
  • 5.7. Hypogonadism
    • 5.7.1. Hypogonadism Market, 2021 - 2033 (USD Million)
  • 5.8. Growth Hormone Deficiency
    • 5.8.1. Growth Hormone Deficiency Market, 2021 - 2033 (USD Million)
  • 5.9. Gender Affirming Therapy
    • 5.9.1. Gender Affirming Therapy Market, 2021 - 2033 (USD Million)
  • 5.10. Fertility Treatment
    • 5.10.1. Fertility Treatment Market, 2021 - 2033 (USD Million)
  • 5.11. Cosmetic Applications
    • 5.11.1. Cosmetic Applications Market, 2021 - 2033 (USD Million)
  • 5.12. Other Indications
    • 5.12.1. Other Indications Market, 2021 - 2033 (USD Million)

Chapter 6. Route of Administration Business Analysis

  • 6.1. U.S. Hormone Therapy (Retail Side) Market: Route of Administration Movement Analysis
  • 6.2. U.S. Hormone Therapy (Retail Side) Market: Route of Administration Segment Dashboard
  • 6.3. Route of Administration Movement & Market Share Analysis, 2024 & 2033
  • 6.4. U.S. Hormone Therapy (Retail Side) Market Estimates & Forecast, by Route of Administration
  • 6.5. Oral
    • 6.5.1. Oral Market, 2021 - 2033 (USD Million)
  • 6.6. Parenteral
    • 6.6.1. Parenteral Market, 2021 - 2033 (USD Million)
  • 6.7. Transdermal
    • 6.7.1. Transdermal Market, 2021 - 2033 (USD Million)
  • 6.8. Other Route of Administration
    • 6.8.1. Other Route of Administration Market, 2021 - 2033 (USD Million)

Chapter 7. Distribution Channel Business Analysis

  • 7.1. U.S. Hormone Therapy (Retail Side) Market: Distribution Channel Movement Analysis
  • 7.2. U.S. Hormone Therapy (Retail Side) Market: Distribution Channel Segment Dashboard
  • 7.3. Distribution Channel Movement & Market Share Analysis, 2024 & 2033
  • 7.4. U.S. Hormone Therapy (Retail Side) Market Estimates & Forecast, by Distribution Channel
  • 7.5. Offline Retail Pharmacies
    • 7.5.1. Offline Retail Pharmacies Market, 2021 - 2033 (USD Million)
    • 7.5.2. Large Chains
      • 7.5.2.1. Large chains market, 2021 - 2033 (USD Million)
    • 7.5.3. Independent Pharmacies
      • 7.5.3.1. Independent pharmacies market, 2021 - 2033 (USD Million)
  • 7.6. Online Pharmacies / Telehealth
    • 7.6.1. Online Pharmacies / Telehealth Market, 2021 - 2033 (USD Million)
    • 7.6.2. Pure-Play Online Pharmacies
      • 7.6.2.1. Pure-play online pharmacies market, 2021 - 2033 (USD Million)
    • 7.6.3. Independent Pharmacies
      • 7.6.3.1. Independent pharmacies market, 2021 - 2033 (USD Million)
  • 7.7. Telehealth & subscription-based DTC brands
    • 7.7.1. Telehealth & subscription-based DTC brands Market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization (Offline Pharmacies)
  • 8.2. Company Categorization (Online Pharmacies)
  • 8.3. Company Categorization (Specialized Hormone Clinics)
  • 8.4. Participant's Overview
    • 8.4.1. Offline Pharmacies
    • 8.4.2. Online Pharmacies
    • 8.4.3. Specialized Hormone Clinics
  • 8.5. Company Market Position Analysis
  • 8.6. Strategy Mapping
    • 8.6.1. Regional Expansion
    • 8.6.2. Mergers & Acquisitions
    • 8.6.3. Others
  • 8.7. Company Profiles/Listing
  • 8.8. Offline Pharmacies
    • 8.8.1. CVS Health
      • 8.8.1.1. Overview
      • 8.8.1.2. Financial performance
      • 8.8.1.3. Product benchmarking
      • 8.8.1.4. Strategic initiatives
    • 8.8.2. Walgreens Boots Alliance, Inc.
      • 8.8.2.1. Overview
      • 8.8.2.2. Financial performance
      • 8.8.2.3. Product benchmarking
      • 8.8.2.4. Strategic initiatives
    • 8.8.3. Walmart Pharmacy
      • 8.8.3.1. Overview
      • 8.8.3.2. Financial performance
      • 8.8.3.3. Product benchmarking
      • 8.8.3.4. Strategic initiatives
    • 8.8.4. Rite Aid Corp
      • 8.8.4.1. Overview
      • 8.8.4.2. Financial performance
      • 8.8.4.3. Product benchmarking
      • 8.8.4.4. Strategic initiatives
    • 8.8.5. The Kroger Co.
      • 8.8.5.1. Overview
      • 8.8.5.2. Financial performance
      • 8.8.5.3. Product benchmarking
      • 8.8.5.4. Strategic initiatives
    • 8.8.6. Albertsons
      • 8.8.6.1. Overview
      • 8.8.6.2. Financial performance
      • 8.8.6.3. Product benchmarking
      • 8.8.6.4. Strategic initiatives
    • 8.8.7. Publix
      • 8.8.7.1. Overview
      • 8.8.7.2. Financial performance
      • 8.8.7.3. Product benchmarking
      • 8.8.7.4. Strategic initiatives
    • 8.8.8. Costco Wholesale Corporation
      • 8.8.8.1. Overview
      • 8.8.8.2. Financial performance
      • 8.8.8.3. Product benchmarking
      • 8.8.8.4. Strategic initiatives
    • 8.8.9. Meijer, Inc.
      • 8.8.9.1. Overview
      • 8.8.9.2. Financial performance
      • 8.8.9.3. Product benchmarking
      • 8.8.9.4. Strategic initiatives
  • 8.9. Online Pharmacies
  • 8.10. Hims & Hers Health, Inc
    • 8.10.1. CVS Health
      • 8.10.1.1. Overview
      • 8.10.1.2. Financial performance
      • 8.10.1.3. Product benchmarking
      • 8.10.1.4. Strategic initiatives
    • 8.10.2. Ro (Roman Health Ventures Inc.)
      • 8.10.2.1. Overview
      • 8.10.2.2. Financial performance
      • 8.10.2.3. Product benchmarking
      • 8.10.2.4. Strategic initiatives
    • 8.10.3. Lemonaid Health, Inc.
      • 8.10.3.1. Overview
      • 8.10.3.2. Financial performance
      • 8.10.3.3. Product benchmarking
      • 8.10.3.4. Strategic initiatives
    • 8.10.4. Mark Cuban Cost Plus Drug Company, PBC
      • 8.10.4.1. Overview
      • 8.10.4.2. Financial performance
      • 8.10.4.3. Product benchmarking
      • 8.10.4.4. Strategic initiatives
    • 8.10.5. Amazon.com, Inc.
      • 8.10.5.1. Overview
      • 8.10.5.2. Financial performance
      • 8.10.5.3. Product benchmarking
      • 8.10.5.4. Strategic initiatives
    • 8.10.6. Blink Health Administration LLC, Inc.
      • 8.10.6.1. Overview
      • 8.10.6.2. Financial performance
      • 8.10.6.3. Product benchmarking
      • 8.10.6.4. Strategic initiatives
    • 8.10.7. GoodRx, Inc
      • 8.10.7.1. Overview
      • 8.10.7.2. Financial performance
      • 8.10.7.3. Product benchmarking
      • 8.10.7.4. Strategic initiatives
    • 8.10.8. Honeybee Health Inc.
      • 8.10.8.1. Overview
      • 8.10.8.2. Financial performance
      • 8.10.8.3. Product benchmarking
      • 8.10.8.4. Strategic initiatives
    • 8.10.9. TruePill
      • 8.10.9.1. Overview
      • 8.10.9.2. Financial performance
      • 8.10.9.3. Product benchmarking
      • 8.10.9.4. Strategic initiatives
    • 8.10.10. NURX Inc.
      • 8.10.10.1. Overview
      • 8.10.10.2. Financial performance
      • 8.10.10.3. Product benchmarking
      • 8.10.10.4. Strategic initiatives
    • 8.10.11. AgelessRx
      • 8.10.11.1. Overview
      • 8.10.11.2. Financial performance
      • 8.10.11.3. Product benchmarking
      • 8.10.11.4. Strategic initiatives
  • 8.11. Specialized Hormone Clinics
  • 8.12. Hims & Hers Health, Inc
    • 8.12.1. BodyLogicMD
      • 8.12.1.1. Overview
      • 8.12.1.2. Financial performance
      • 8.12.1.3. Product benchmarking
      • 8.12.1.4. Strategic initiatives
    • 8.12.2. Defy Medical
      • 8.12.2.1. Overview
      • 8.12.2.2. Financial performance
      • 8.12.2.3. Product benchmarking
      • 8.12.2.4. Strategic initiatives
    • 8.12.3. Renew Vitality
      • 8.12.3.1. Overview
      • 8.12.3.2. Financial performance
      • 8.12.3.3. Product benchmarking
      • 8.12.3.4. Strategic initiatives
    • 8.12.4. Victory Men's Health
      • 8.12.4.1. Overview
      • 8.12.4.2. Financial performance
      • 8.12.4.3. Product benchmarking
      • 8.12.4.4. Strategic initiatives
    • 8.12.5. Hone Health
      • 8.12.5.1. Overview
      • 8.12.5.2. Financial performance
      • 8.12.5.3. Product benchmarking
      • 8.12.5.4. Strategic initiatives
    • 8.12.6. Joi & Blokes
      • 8.12.6.1. Overview
      • 8.12.6.2. Financial performance
      • 8.12.6.3. Product benchmarking
      • 8.12.6.4. Strategic initiatives
    • 8.12.7. Ways2Well
      • 8.12.7.1. Overview
      • 8.12.7.2. Financial performance
      • 8.12.7.3. Product benchmarking
      • 8.12.7.4. Strategic initiatives
    • 8.12.8. Honeybee Health Inc.
      • 8.12.8.1. Overview
      • 8.12.8.2. Financial performance
      • 8.12.8.3. Product benchmarking
      • 8.12.8.4. Strategic initiatives
    • 8.12.9. 4Ever Young Anti-aging Solutions
      • 8.12.9.1. Overview
      • 8.12.9.2. Financial performance
      • 8.12.9.3. Product benchmarking
      • 8.12.9.4. Strategic initiatives
    • 8.12.10. T CLINICS USA
      • 8.12.10.1. Overview
      • 8.12.10.2. Financial performance
      • 8.12.10.3. Product benchmarking
      • 8.12.10.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. hormone therapy (Retail Side) market, by product, 2021 - 2033 (USD Million)
  • Table 4 U.S. Hormone Therapy (Retail Side) Market: Strategy Mapping by Product
  • Table 5 U.S. hormone therapy (Retail Side) market, by indication, 2021 - 2033 (USD Million)
  • Table 6 U.S. Hormone Therapy (Retail Side) Market: Product and Strategy Mapping by Indication
  • Table 7 U.S. hormone therapy (Retail Side) market, by route of administration, 2021 - 2033 (USD Million)
  • Table 8 U.S. Hormone Therapy (Retail Side) Market: Route of Administration and Strategy Mapping by Route of Administration
  • Table 9 U.S. hormone therapy (Retail Side) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 10 U.S. Hormone Therapy (Retail Side) Market: Distribution Channel and Strategy Mapping by Route of Administration

List of Figures

  • Fig. 1 U.S. hormone therapy (Retail Side) market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Segment outlook
  • Fig. 10 Segment outlook
  • Fig. 11 Competitive landscape
  • Fig. 12 U.S. hormone therapy (Retail Side) market lineage outlook
  • Fig. 13 U.S. hormone therapy (Retail Side) market dynamics
  • Fig. 14 Market driver relevance analysis (Current & future impact)
  • Fig. 15 Market restraint relevance analysis (Current & future impact)
  • Fig. 16 U.S. hormone therapy (Retail Side) market: PESTLE analysis
  • Fig. 17 U.S. hormone therapy (Retail Side) market: Porter's five forces analysis
  • Fig. 18 U.S. hormone therapy (Retail Side) market: Product segment dashboard
  • Fig. 19 U.S. hormone therapy (Retail Side) market: Product market share analysis, 2024 & 2033
  • Fig. 20 Sex hormones market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 21 Estrogen Replacement Therapy (ERT) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Testosterone Replacement Therapy (TRT) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Progesterone therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Combined hormone therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Thyroid hormones market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Growth hormones market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Adrenal hormones market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Other hormones market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 U.S. hormone therapy (retail side) market: Indication outlook key takeaways
  • Fig. 30 U.S. Hormone Therapy (Retail Side) Market: Indication Movement Analysis (USD Million)
  • Fig. 31 Menopause & andropause management market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Hypothyroidism market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Hypogonadism market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Growth hormone deficiency market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Gender affirming therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Fertility treatment market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Cosmetic applications market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 U.S. hormone therapy (retail side) market: Route of administration outlook key takeaways
  • Fig. 40 U.S. Hormone Therapy (Retail Side) Market: Route of Administration Movement Analysis (USD Million)
  • Fig. 41 Oral market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Parenteral market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Transdermal market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 U.S. hormone therapy (retail side) market: Distribution channel outlook key takeaways
  • Fig. 46 U.S. Hormone Therapy (Retail Side) Market: Distribution Channel Movement Analysis (USD Million)
  • Fig. 47 Offline retail pharmacies market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Large chains market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Independent pharmacies market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Online pharmacies / telehealth market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Pure-play online pharmacies market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Telehealth & subscription-based DTC brands market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Others (specialized hormone clinics) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Competition categorization (Offline Pharmacies)
  • Fig. 55 Competition categorization (Online Pharmacies)
  • Fig. 56 Competition categorization (Specialized Hormone Clinics)
  • Fig. 57 Company market position analysis
  • Fig. 58 Company market position analysis
  • Fig. 59 Company market position analysis
  • Fig. 60 Strategy mapping